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ABSTRACT 
Objectives: To compare the compatibility and chemical stability of ondansetron hydrochloride/naloxone hydrochloride and metoclopramide 
hydrochloride/naloxone hydrochloride admixtures used in palliative care units at three different storage conditions (4˚C, 22 ˚C and 37˚C) for 192 
hours. 
Methods: A high performance liquid chromatography-mass spectrometry (LC-MS) analytical method was established to investigate the chemical 
stability of the combinations.  
Results: Metoclopramide hydrochloride and naloxone hydrochloride concentrations remain above 90% of their initial concentration under all 
storage conditions for 192 hours, while ondansetron hydrochloride remain stable at 4˚C and 22˚C but it losses up to 15.03% of its initial 
concentration when stored for 192 hours at 37 ˚C. 
Conclusion: metoclopramide hydrochloride and naloxone hydrochloride admixture is more stable and preferred to ondansetron hydrochloride and 
naloxone hydrochloride admixture under all storage conditions. 
Keywords: Palliative care-liquid chromatography-mass spectrometry-high performance liquid chromatography-ondansetron hydrochloride-
metoclopramide hydrochloride-naloxone hydrochloride. 
 
INTRODUCTION 
The administration of painkillers, such as analgesics in palliative 
care of patients suffering from serious life-threatening diseases such 
as cancer is an essential part of pharmaceutical care in the hospitals. 
The main aim of palliative care is to prevent or treat the symptoms 
and side effects of the disease and its treatment [1]. Therefore, 
different drug combinations in a small volumes delivered to the 
patients by a syringe driver are used to overcome most of the 
annoying symptoms and side effects associated with fatal disease or 
its treatment. 
Among the potential problems of mixing injections include 
degradation of the drug(s) and this may result in drugs 
precipitation/crystallization with potentially reduced drug efficacy. 
The greater the number of injections mixed together, the greater the 
possibilities of drug-drug interactions and changes in the physical 
nature of the drugs. Chemical stability and compatibility studies data 
are only available for a few of the subcutaneous and intravenous 
injection combinations used in palliative care; injection 
combinations are often used in practice without any prior 
assessment of the chemical or even physical stability of the 
admixture. In July 2009, the Medicines and Healthcare Products 
Regulatory Agency (MHRA, UK) published the outcome of its 
consultation regarding the legal position of practitioners mixing and 
administering medicines in palliative care together with the 
Commission on Human Medicines’ recommendations for changes to 
medicines legislation.  
The changes proposed apply not only to palliative care but to all 
clinical areas where the mixing of medicines is acceptable practice. 
The Commission’s recommendations have been accepted by 
Ministers and will a) allow doctors and dentists to direct other to 
mix, b) allow non-medical prescribers to mix medicines themselves 
and direct others to mix, and c) allow nurse and pharmacist, 
independent prescribers, to prescribe unlicensed medicines for their 
patients on the same basis as doctors and supplementary 
prescribers [2]. As the MHRA intends to extend the types of 
practitioners authorized to be involved in the mixing of medicines 
and the situations where mixing of medicines is acceptable, there 
could well be an increase in the number of medicines that are mixed. 
This will certainly require an assessment of the physical and 
chemical stability of drugs when medicines are mixed. While many 
medicines are may be assumed to be stable under this situation, 
without investigation, the stability of such combinations should not 
be assumed. 
Opioids are the first line choice for the palliative care provider to 
control moderate to severe pain associated with cancer patients [3]. 
However, opioids have serious aggravating side effects such as 
nausea, vomiting, respiratory depression, sedation and constipation 
[4-6]. Therefore, ondansetron hydrochloride, metoclopramide 
hydrochloride and naloxone hydrochloride are considered essential 
medicines in palliative care to reverse opioid’s side effects. 
Ondansetron hydrochloride (Zofran) is a new serotonin subtype 3 
(5-HT3) receptor antagonist used to prevent or treat nausea and 
vomiting [7], whereas metoclopramide hydrochloride belongs to 
dopamine antagonist antiemetic class. In the other hand, naloxone 
hydrochloride is an opiate antagonist used for complete or partial 
reversal of respiratory depression induced by opioids [8]. Although 
metoclopramide hydrochloride has a serious side effects such as 
involuntary movement of the face, tongue, extremities and 
neuroleptic malignant syndrome, it is still prescribed as a powerful 
antiemetic to control nausea and vomiting despite of ondansetron 
has been reported in literature to be more effective with fewer side 
effects in prevention of postoperative nausea and vomiting [9]. In 
palliative care, although both subcutaneous injections of 4 mg/ml 
ondansetron hydrochloride [10, 11] and intravenous infusions of 
metoclopramide hydrochloride 2 mg/Kg [12] are recommended to 
control nausea and vomiting, 0.2 mg/ml of naloxone hydrochloride 
[13, 14] can be mixed with both formulations to manage respiratory 
depression occur due to the use of opioids to overcome moderate 
and severe pain. Although the admixtures considered to be 
compatible, physically and chemically stable at 4̊C  [15] and 22̊C  
[16], admixtures physical and chemical stability weren’t compared 
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and investigated at higher storage temperatures and hot climate. In 
the current study, a comparison between admixtures of ondansetron 
hydrochloride (0.4 mg/ml)/naloxone hydrochloride (0.2 mg/ml) 
and metoclopramide (0.2 mg/ml)/naloxone hydrochloride (0.2 
mg/ml) in 0.9% sodium chloride were stored at 3 different 
temperatures (4, 22, 37 ⁰C) for 8 days to indicate the more stable 
and compatible admixture to be used more safely in temperatures 
higher than 4˚C. 
METHODS AND MATERIALS 
Chemicals and materials 
High performance liquid chromatography (HPLC) grade acetonitrile, 
ammonium acetate Analytical and acetic acid were obtained from 
Sigma Aldrich (Dor-set, UK). HPLC grade water was prepared ‘‘in 
house’’ with a MilliQ filter (Millipore, Watford, UK). 
Ondansetron hydrochloride (Zofran) was available as 8 mg/4 ml 
ampoules (Glaxo Wellcome, Italy), metoclopramide hydrochloride 
powder was purchased from Sigma-aldrich (USA), naloxone 
hydrochloride was available as 0.4 mg/ml ampoules from HIKMA 
Pharmaceuticals (Amman, Jordan). 
Three-part, polypropylene Luer-LokTM syringes (30 mL) were 
obtained from Becton Dickinson (Oxford, UK), and Helapet Combi-
Caps from B. Braun (Melsungen, Germany). 
Preparation of the combination studied 
Stock solutions containing 1 mg/ml of both ondansetron 
hydrochloride/naloxone hydrochloride dehydrate dissolved in 
0.9% sodium chloride solution and 1 mg/ml of both 
metoclopramide hydrochloride/naloxone hydrochloride dihydrate 
dissolved in 0.9% sodium chloride solution were prepared. 
Linearity of response around the nominal content in both 
injections was achieved with six concentrations ranging from 25 to 
125 % diluted with 0.1% ammonium acetate in water (pH 4.5): 
acetonitrile (70:30 v/v).  
Each admixture were prepared in duplicate and stored at 22̊C, 
37˚C and 4˚C. Samples were analyzed at zero minutes, 24, 48, 96 
and 192 hours. 
pH measurement 
The combinations were diluted X5 with HPLC grade water, and the 
pH of the diluted solution was measured with a pH meter that was 
calibrated with buffers at pH 4 and pH 7. 
Instrumentation 
The HPLC system (Waters 2690 Separation Module) used in this 
analytical method consisted of a Waters 600E multi solvent delivery 
system pump, a Waters Ultra WISP 715 auto-injector, and a Waters 
996 diode-array detection system. Chromatographic separation was 
performed using Waters XTerra RP 18 (5 µm, 250 x 4.6 mm i. d) 
column 
Chromatographic conditions 
Mobile phase comprised of filtered and degassed 0.1% w/v 
ammonium acetate in water (pH 4.5) and acetonitrile in proportion 
of 70:30 v/v and pumped at a flow rate of 1 ml/min. Samples were 
analyzed at a wavelength of 240 nm and were injected at 10 µm 
injection volume. In LC-MS, the same conditions as were used in 
HPLC but at a flow rate of 2 ml/min. LC was directly attached to the 
ESI of triple quadrupole. 
Degradation 
One milliliter of each admixture was placed in a 4 mL vial to which 1 
mL of 1 M HCl was added. Samples were heated to 90 ˚C for 90 min, 
then allowed to cool down for 15 min and analyzed by liquid 
chromatography–mass spectrometry (LC–MS). 
LC-MS 
Tandem MS was performed by a Waters Alliance 2695 Separations 
Module HPLC, equipped with a quaternary pump and an automatic 
interfaced to a Micromass Quattro micro API (triple quadrupole) 
mass spectrometer equipped with a Z-spray electrospray (ESI) 
ionization source was used. Nitrogen as drying, as well as nebulizing 
gas, was generated from pressurized air in a NG-7 nitrogen 
generator. The nebulizing gas flow was set to 50 L/h and the gas 
flow desolvation to 550 L/h.  
The optimized values were: capillary voltages, 4.5 kV; extractor 
voltage, 2 V; source temperature; 100 ˚ C; desolvation temperature, 
400 ˚C; and multiplier; 650 V. 
RESULTS 
Samples of ondansetron hydrochloride/naloxone hydrochloride and 
metoclopramide hydrochloride/naloxone hydrochloride admixtures 
were stored at three storage conditions 4 ˚ C, 22 ˚ C and 37 ˚ C and 
analyzed at 0 minutes, 4, 24, 48, 96, 192. fig. 1 shows the 
chromatogram obtained for ondansetron hydrochloride and 
naloxone hydrochloride combination after storage at 37 ˚C for 24 
hours, while fig. 2 shows the chromatogram obtained for 
ondansetron hydrochloride and naloxone hydrochloride 
combination in the same storage conditions after 192 hours. 
 
 
Fig. 1: High-performance liquid chromatography analysis of 
an injection combination containing ondansetron 
hydrochloride (0.4 mg/ml) and naloxone hydrochloride (0.2 
mg/ml) in 0.9% water of injection (sodium chloride) after 24 
hours storage at 37 ˚C 
 
 
Fig. 2: High-performance liquid chromatography analysis of 
an injection combination containing ondansetron 
hydrochloride (0.4 mg/ml) and naloxone hydrochloride (0.2 
mg/ml) in 0.9% water of injection (sodium chloride) after 8 
days storage at 37 ˚C 
 
Tables [1-6] show the set of data obtained for ondansetron 
hydrochloride/naloxone hydrochloride and metoclopramide 
hydrochloride/naloxone hydrochloride admixtures under fridge 
temperature (4 ˚C), room temperature (22 ˚C) and 37 ˚C. 
Abbreviations 
RSD: Relative standard deviation 
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Table 1: Stability data for admixture injection containing ondansetron hydrochloride (0.4 mg/ml) and naloxone hydrochloride (0.2 
mg/ml) under light exposure at room temperature (22 ˚C) 
 Ondansetron hydrochloride % remaining Naloxone hydrochloride% remaining 
Time (h) Syr.1 Syr.2 RSD% Syr.1 Syr.2 RSD% 
0 100.0% 100.0% 0.0% 100. 0% 100.0% 0.0% 
4 97.61% 97.45% ±0.1% 98.27% 98.26% 0.0% 
24 97.25% 97.35% ±0.1% 98.09% 98.06% 0.0% 
48 97.05% 97.23% ±0.1% 97.31% 97.76% ±0.3% 
96 96.87% 96.76% ±0.1% 97.02% 97.01% 0.0% 
192 95.88% 95.88% 0.0% 96.13% 96.00% ±0.1% 
 
Table 2: Stability data for admixture injection containing ondansetron hydrochloride (0.4 mg/ml) and naloxone hydrochloride (0.2 
mg/ml) under light exposure at room temperature (4 ˚C) 
 Ondansetron hydrochloride % remaining Naloxone hydrochloride% remaining 
Time (h) Syr.1 Syr.2 RSD% Syr.1 Syr.2 RSD% 
0 100.0% 100.0% 0.0% 100. 0% 100.0% 0.0% 
4 98.52% 98.72% ±0.1% 97.32% 97.44% ±0.1% 
24 98.28% 98.66% ±0.3% 97.28% 97.29% 0.0% 
48 98.19% 97.92% ±0.2% 97.12% 96.73% ±0.3% 
96 98.09% 97.28% ±0.6% 96.80% 96.35% ±0.3% 
192 97.87% 97.17 ±0.5% 96.61% 96.19 ±0.3% 
 
Table 3: Stability data for admixture injection containing ondansetron hydrochloride (0.4 mg/ml) and naloxone hydrochloride (0.2 
mg/ml) under light exposure at room temperature (37 ˚C) 
 Ondansetron hydrochloride % remaining Naloxone hydrochloride% remaining 
Time (h) Syr.1 Syr.2 RSD% Syr.1 Syr.2 RSD% 
0 100.0% 100.0% 0.0% 100. 0% 100.0% 0.0% 
4 97.39% 98.25% ±0.6% 97.93% 97.81% ±0.1% 
24 93.35% 96.85% ±2.6% 94.51% 95.32% ±0.6% 
48 90.62% 92.66% ±1.6% 93.30% 92.97% ±0.3% 
96 88.33% 90.89% ±2.0% 91.85% 91.05% ±0.6% 
192 84.97% 86.12% ±1.0% 90.05% 90.27% ±0.2% 
 
Table 4: Stability data for admixture injection containing metoclopramide hydrochloride (0.2 mg/ml) and naloxone hydrochloride (0.2 
mg/ml) under light exposure at room temperature (22⁰C) 
 Metoclopramide hydrochloride % remaining Naloxone hydrochloride% remaining 
Time (h) Syr.1 Syr.2 RSD% Syr.1 Syr.2 RSD% 
0 100.0% 100.0% 0.0% 100% 0% 100.0% 0.0% 
4 99.7% 99.5% ±0.1% 99.4% 98.35% ±0.8% 
24 99.5% 99.5% 0.0% 99.4% 98.17% ±0.9% 
48 98.89% 98.77% ±0.1% 97.95% 97.73% ±0.2% 
96 98.33% 98.16% ±0.1% 95.72% 97.58% ±1.4% 
192 97.61% 97.35% ±0.2% 95.12% 96.90% ±1.3% 
 
Table 5: Stability data for admixture injection containing metoclopramide hydrochloride (0.2 mg/ml) and naloxone hydrochloride (0.2 
mg/ml) under light exposure at (4 ˚C) 
 Metoclopramide hydrochloride % remaining Naloxone hydrochloride% remaining 
Time (h) Syr.1 Syr.2 RSD% Syr.1 Syr.2 RSD% 
0 100.0% 100.0% 0.0% 100. 0% 100.0% 0.0% 
4 99.98% 99.86% ±0.1% 99.63% 99.65% ±0.01% 
24 99.00% 99.53% ±0.4% 98.69% 99.21% ±0.4% 
48 97.61% 97.95% ±0.3% 96.07% 96.88% ±0.6% 
96 97.44% 97.22% ±0.1% 96.05% 96.61% ±0.4% 
192 95.96% 96.88% ±0.7% 95.71% 96.28% ±0.4% 
 
Table 6: Stability data for admixture injection containing metoclopramide hydrochloride (0.2 mg/ml) and naloxone hydrochloride (0.2 
mg/ml) under light exposure at (37 ˚C) 
 Ondansetron hydrochloride % remaining Naloxone hydrochloride% remaining 
Time (h) Syr.1 Syr.2 RSD% Syr.1 Syr.2 RSD% 
0 100.0% 100.0% 0.0% 100. 0% 100.0% 0.0% 
4 99.93% 98.72% ±0.03% 99.89% 99.42% ±0.5% 
24 99.76% 97.91% ±0.4% 99.27% 98.88% ±0.7% 
48 98.71% 95.72% ±0.2% 99.01% 97.99% ±1.7% 
96 97.03% 95.49% ±0.3% 97.42% 96.20% ±0.5% 
192 95.81% 95.38% ±0.2% 96.06% 95.86% ±0.4% 
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Degradant peak eluted at around 4.3 minutes was identified by using Tandem MS as shown in fig. 3. 
 
 




Although ondansetron hydrochloride and metoclopramide 
hydrochloride were recommended to be administered in 4 mg/ml 
and 2 mg/Kg respectively, concentrations were reduced to 0.4 
mg/ml and 0.2 mg/ml correspondingly to be within the instrument 
range. The calibration curves for ondansetron hydrochloride/ 
naloxone hydrochloride and metoclopramide hydrochloride/ 
naloxone hydrochloride were linear over the range between 25% 
and 200% of the stated content for ondansetron hydrochloride, 
metoclopramide hydrochloride and naloxone hydrochloride in 0.9% 
sodium chloride infusion. Moreover, the stability indicating high 
performance liquid chromatography assay method for the indication 
and quantification of metoclopramide was very simple and capable 
to produce resolved and symmetrical peaks with reasonable 
retention time compared with the literature reported assays [17] 
which used an ion-pairing agent and complex mobile phase 
composition. Method precision was tested by preparing 6 samples of 
each admixture and analyzed using the chromatographic conditions. 
The relative standard deviation of peak area obtained for 
ondansetron hydrochloride, metoclopramide hydrochloride and 
naloxone hydrochloride were±0.6%,±0.4% and±0.9%, respectively. 
Under the examined conditions, one degradant peak is clearly eluted 
before ondansetron hydrochloride peak. Relatively small amounts of 
degradant were noticeable for ondansetron hydrochloride under 
room temperature (22 ˚C) and fridge temperature (4 ˚C) for 8 days.  
While after 8 days storage at 37 ˚C, ondansetron hydrochloride was 
prone to degradation up to 15.02%. In contrast, metoclopramide 
hydrochloride and naloxone remain above 90% of their initial 
concentration under all storage conditions for 8 days. Degradant peak 
is formed after 4 days at all storage conditions, the area of the 
degradant peak increased as the temperature increased. The 
identification of degradant was performed using Tandem MS and it 
was due to the formation of ondansetron related compound A 
(3[(dimethylamino) methyl]-1,2,3,9-tetrahydro-9-methyl-4H-carbazol 
-4-one) as stated in European pharmacopeia [18]. On the other hand, 
metoclopramide hydrochloride and naloxone hydrochloride 
admixture formulation remain stable for 8 days under all storage 
conditions and there was not any detectable traces of degradants. 
However metoclopramide hydrochloride/naloxone hydrochloride 
admixture showed no color change during all storage conditions for 
8 days, visual inspection of ondansetron hydrochloride/naloxone 
hydrochloride admixture showed that the appearance changed with 
time going from a clear, colorless solution when prepared to a 
brown-colored solution, this became noticeable after 6 days. Apart 
from the dis coloration of ondansetron hydrochloride/naloxone 
hydrochloride admixture from visual inspection, there was no 
evidence of particulate formation and the pH of ondansetron 
hydrochloride/naloxone hydrochloride was reduced over 192 
hours, while metoclopramide hydrochloride/naloxone hydro 
chloride admixture pH remained stable over 192 h for both 
admixtures. In addition, degradation study showed that ondansetron 
hydrochloride was degraded in 1 M hydrochloric acid to form 
ondansetron related compound A, while metoclopramide 
hydrochloride remain stable. 
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